Cargando…

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel

SIMPLE SUMMARY: In prostate cancer patients with rising prostate-specific antigens (PSAs) after primary local therapy, and at high risk of metastatic disease based on a high Gleason score or ISUP grades 4–5 and/or short PSA doubling time, androgen-deprivation therapy (ADT) was shown to be effective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carrot, Aurore, Elaidi, Reza-Thierry, Colomban, Olivier, Maillet, Denis, Tod, Michel, You, Benoit, Oudard, Stéphane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834031/ https://www.ncbi.nlm.nih.gov/pubmed/35159082 http://dx.doi.org/10.3390/cancers14030815

Ejemplares similares

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

PSA kinetics before 40 years of age
por: Pazeto, Cristiano Linck, et al.
Publicado: (2018)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
por: Kobayashi, Minoru, et al.
Publicado: (2023)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*
por: Wilbaux, M, et al.
Publicado: (2015)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

PSA 1972 : proceedings of the 1972 biennial meeting philosophy of science association
Publicado: (1974)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Theory of stellar pulsation (PSA-2)
por: Cox, John P
Publicado: (2017)

Multiparametric MRI in the PSA Screening Era
por: George, Arvin K., et al.
Publicado: (2014)

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

PSA mass screening: is there enough evidence?
por: Rocco, Bernardo, et al.
Publicado: (2012)

Rheological and Mechanical Properties of an Acrylic PSA
por: Simões, Beatriz D., et al.
Publicado: (2023)

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis
por: Mahal, Brandon A., et al.
Publicado: (2023)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
por: Frasca, Loredana, et al.
Publicado: (2018)

PsaF Is a Membrane-Localized pH Sensor That Regulates psaA Expression in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2021)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer
por: Gentile, Francesco, et al.
Publicado: (2023)

Predictors of PSA Screening Among Men Over 40 Years of Age Who Had Ever Heard about PSA
por: Seo, Hyung Seok, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t2qktp9fop9kr8ig7psnc3n99h